Skip to main content
Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
0.845
+0.067 (8.67%)
At close: Nov 22, 2024, 4:00 PM
0.860
+0.015 (1.78%)
After-hours: Nov 22, 2024, 4:11 PM EST

Karyopharm Therapeutics Revenue

Karyopharm Therapeutics had revenue of $38.78M in the quarter ending September 30, 2024, with 7.70% growth. This brings the company's revenue in the last twelve months to $148.44M, up 1.77% year-over-year. In the year 2023, Karyopharm Therapeutics had annual revenue of $146.03M, down -7.03%.

Revenue (ttm)
$148.44M
Revenue Growth
+1.77%
P/S Ratio
0.68
Revenue / Employee
$456,745
Employees
325
Market Cap
105.89M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023146.03M-11.04M-7.03%
Dec 31, 2022157.07M-52.75M-25.14%
Dec 31, 2021209.82M101.73M94.12%
Dec 31, 2020108.09M67.19M164.31%
Dec 31, 201940.89M10.56M34.80%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
FONAR 102.01M
Akoya Biosciences 86.82M
Coya Therapeutics 9.55M
Avalo Therapeutics 820.00K
Inovio Pharmaceuticals 203.41K
INmune Bio 42.00K
Revenue Rankings

KPTI News

More News